MedTrace Logo

Epidiolex and Drug Resistant Epilepsy in Children

NCT02397863 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2015-04-24

No results posted yet for this study

Summary

This open-label, multi-center study is open to patients 1 to 18 years of age at time of enrollment with medication resistant epilepsy.

Conditions

Interventions

DRUG

Cannabidiol (Epidiolex)

Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.

Sponsors & Collaborators

  • State of Georgia

    collaborator UNKNOWN

  • Augusta University

    lead OTHER

Principal Investigators

  • Yong D Park, MD · Professor

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2019-12-31
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02397863 on ClinicalTrials.gov